reports
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 March 2025 in which we reassessed the appropriateness of the rati...
Charles River Laboratories to Present at Barclays Global Healthcare Co...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...
Charles River Announces Agreement with Singapore General Hospital
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and manufacture allogeneic chimeric antigen receptor (CAR) T-cells which will be used to treat patients with cancer. “We are thrilled to leverage our cell line characterization services and comprehensive NGS testing app...
Charles River Laboratories International Inc: 3 directors
Three Directors at Charles River Laboratories International Inc bought/sold/sold after exercising options 11,989 shares at between 162.500USD and 165.010USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart whi...
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.1%, and an acquisition contributed 0.9% to consolidated fourth-quarter revenue. A divestiture reduced reported revenue by 0.1%. Excluding the effect of these items, revenue declined 1.8% on an organic basis. On a seg...
Charles River and Deciphex Extend Global Partnership to Expand Digital...
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, today announced the next phase of a strategic collaboration to focus on advancing cutting-edge image management solutions, while continuing to develop novel artificial intelligence (AI) tools for toxicologic pathology. Together, Deciphex and Charles River will deliver a fully integrated image management, distribution, and archiving workflow designed to maximize efficiency, precision, and scalability in pathology workflows. This press ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ADI ANALOG DEVICES INC.
TXN TEXAS INSTRUMENTS INCORPORATED
SCCO SOUTHERN COPPER CORPORATION
POWI POWER INTEGRATIONS INC.
ON ON SEMICONDUCTOR CORPORATION
MOD MODINE MANUFACTURING COMPANY
MCHP MICROCHIP TECHNOLOGY INCORPORATED
LDOS LEIDOS HOLDINGS INC.
JJSF J & J SNACK FOODS CORP.
HSY HERSHEY COMPANY
GPRE GREEN PLAINS INC.
GGG GRACO INC.
GD GENERAL DYNAMICS CORPORATION
FORM FORMFACTOR INC.
FCX FREEPORT-MCMORAN INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ASH ASHLAND GLOBAL HOLDINGS INC.
APOG APOGEE ENTERPRISES INC.
BCPC BALCHEM CORPORATION
TECK.B TECK RESOURCES LIMITED CLASS B
COHU COHU INC.
CRUS CIRRUS LOGIC INC.
ENTG ENTEGRIS INC.
FSLR FIRST SOLAR INC.
LMT LOCKHEED MARTIN CORPORATION
NX QUANEX BUILDING PRODUCTS CORPORATION
WFT.. WEATHERFORD INTERNATIONAL PLC
RDY DR. REDDY'S LABORATORIES LTD. ADS
PI IMPINJ INC.
BHP BHP GROUP
ICHR ICHOR HOLDINGS LTD.
RTP.. RIO TINTO PLC ADS (MEXICO)
AMD ADVANCED MICRO DEVICES INC.
ELD ELDORADO GOLD CORPORATION
CFB CROSSFIRST BANKSHARES
LHX L3HARRIS TECHNOLOGIES INC
HII. HORIZONS CDN INS
RVMD REVOLUTION MEDICINES
CARR CARRIER GLOBAL CORP.
UTZ UTZ BRANDS INC (A)
OTIS OTIS WORLDWIDE CORPORATION
FLNC FLUENCE ENERGY INC
STM STABILUS SE
ELVN IMARA INC
HEI HAWAIIAN ELECTRIC CO INC COM
AMKR 21SHARES MAKER ETP
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and ...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2024 financial results and provide 2025 guidance on Wednesday, February 19th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 19th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles Rive...
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Exper...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of , a secure cloud-based platform that enhances leading vivarium rental services through a digital platform that connects clients effortlessly with the training, tools and services needed to start research quickly. As a digital companion to offering, Apollo's centralized dashboard seamlessly connects clients to online training, Charles River’s Research Models Online Ordering System, and other study support services. “Apollo is the tech stack that is powering Charles Ri...
Charles River and Akron Bio Announce Collaboration to Enhance Operatio...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell Therapy Flex Platform for Process Development. The integration of Akron’s line of liquid cytokines further enables closed system processing, which streamlines operations, minimizes risk, and improves process robustnes...
Charles River Laboratories to Present at J.P. Morgan Healthcare Confer...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation ...
Charles River Introduces Global Biotech Incubator Program
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio,” said Kerstin Dolp...
Charles River Laboratories to Present at Evercore ISI Investor Confere...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...
Charles River Laboratories to Present at UBS and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12th, at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20th, at 2:00 p.m. GMT (9:00 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles Rive...
Charles River Laboratories Announces Third-Quarter 2024 Results
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue. A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 2.7% on an organic basis. On a segment basi...
Charles River Launches New Retrogenix® Non-Human Protein Library
WILMINGTON, Mass.--(BUSINESS WIRE)-- (NYSE: CRL) today announced the launch of the . The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection. “Developed in-house using the innovative and unique Retrogenix® platform, the new library provides early insights into how therapeutics interact with non-human protein targets in vitro,” said Aidan Synnott, Ph.D., Corporate Vice President, Global Discovery. “These early insights are generated without the lead time and expense associ...
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Relea...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to ...
Charles River Provides Translational Expertise at Neuroscience 2024
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe, will take place from October 5-9 in Chicago, IL. “Charles River is committed to changing the course of neuroscience research,” said Antti Nurmi, Ph.D., MSc, General Manager, CNS Pharmacol...
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica...
WILMINGTON, Mass.--(BUSINESS WIRE)-- (NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize to progress critical brain disease research. “We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease,” said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck’s industry-leading neurology expertise, we look forward to a successful collaboration.” Logica...
Charles River Laboratories and CEBINA Announce Strategic Collaboration...
WILMINGTON, Mass. & VIENNA--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announced a strategic collaboration within the acceleration program DanubeNeuro, an initiative focused on identifying and advancing pioneering academic research projects with the potential to create new drugs and innovative technologies in the field of neurodegeneration. CEBINA’s acceleration program identifies and develops pioneering research projects with the potential to create innovative drugs, diagnostic metho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.